To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with nested case-control analysis, in primary care.
COVID-19
Home-care
Paracetamol
Prescribing pattern
Safety profile
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
03
06
2022
accepted:
11
07
2022
pubmed:
31
7
2022
medline:
16
11
2022
entrez:
30
7
2022
Statut:
ppublish
Résumé
This study aimed to compare the prescribing patterns of paracetamol in COVID-19 with those for similar respiratory conditions and investigated the association between paracetamol use and COVID-19-related hospitalization/death. Using a primary care data source, we conducted a cohort study to calculate the incidence rate of paracetamol use in COVID-19 and for similar respiratory conditions in 2020 and 2019 (i.e. pre-pandemic phase), respectively. In the study cohort, we nested a case-control analyses to investigate the association between paracetamol use and COVID-19-related hospitalizations/deaths. Overall, 1554 (33.4 per 1000) and 2566 patients (78.3 per 1000) were newly prescribed with paracetamol to treat COVID-19 or other respiratory conditions, respectively. Those aged 35-44 showed the highest prevalence rate (44.7 or 99.0 per 1000), while the oldest category reported the lowest value (17.8 or 39.8 per 1000). There was no association for early (OR = 1.15; 95% CI: 0.92-1.43) or mid-term (OR = 1.29; 95% CI: 0.61-2.73) users of paracetamol vs. non-users. Instead, the late users of paracetamol showed a statistically significant increased risk of hospitalization/death (OR = 1.75; 95% CI: 1.4-2.2). Our findings provide reassuring evidence on the use and safety profile of paracetamol to treat early symptoms of COVID-19 as in other respiratory infections.
Sections du résumé
BACKGROUND AND OBJECTIVE
This study aimed to compare the prescribing patterns of paracetamol in COVID-19 with those for similar respiratory conditions and investigated the association between paracetamol use and COVID-19-related hospitalization/death.
METHODS
Using a primary care data source, we conducted a cohort study to calculate the incidence rate of paracetamol use in COVID-19 and for similar respiratory conditions in 2020 and 2019 (i.e. pre-pandemic phase), respectively. In the study cohort, we nested a case-control analyses to investigate the association between paracetamol use and COVID-19-related hospitalizations/deaths.
RESULTS
Overall, 1554 (33.4 per 1000) and 2566 patients (78.3 per 1000) were newly prescribed with paracetamol to treat COVID-19 or other respiratory conditions, respectively. Those aged 35-44 showed the highest prevalence rate (44.7 or 99.0 per 1000), while the oldest category reported the lowest value (17.8 or 39.8 per 1000). There was no association for early (OR = 1.15; 95% CI: 0.92-1.43) or mid-term (OR = 1.29; 95% CI: 0.61-2.73) users of paracetamol vs. non-users. Instead, the late users of paracetamol showed a statistically significant increased risk of hospitalization/death (OR = 1.75; 95% CI: 1.4-2.2).
CONCLUSIONS
Our findings provide reassuring evidence on the use and safety profile of paracetamol to treat early symptoms of COVID-19 as in other respiratory infections.
Identifiants
pubmed: 35908013
doi: 10.1007/s11739-022-03054-1
pii: 10.1007/s11739-022-03054-1
pmc: PMC9362076
doi:
Substances chimiques
Acetaminophen
362O9ITL9D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2237-2244Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).
Références
Br J Clin Pharmacol. 2021 Mar;87(3):776-784
pubmed: 32805057
J Med Virol. 2021 Oct;93(10):5704-5706
pubmed: 34170556
Drug Saf. 2020 Aug;43(8):699-709
pubmed: 32572842
Osteoarthritis Cartilage. 2016 May;24(5):763-4
pubmed: 26802548
Pharmacoepidemiol Drug Saf. 2006 May;15(5):291-303
pubmed: 16447304
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358
Br J Clin Pharmacol. 2015 Oct;80(4):779-80
pubmed: 26119706
J Public Health Med. 2003 Sep;25(3):254-7
pubmed: 14575204
PLoS Med. 2021 Sep 28;18(9):e1003777
pubmed: 34582457
Bone. 2012 Jan;50(1):85-90
pubmed: 21985999
Int J Cardiol. 2016 Nov 15;223:701-705
pubmed: 27568993
Basic Clin Pharmacol Toxicol. 2022 Feb;130(2):225-239
pubmed: 34811895
J Clin Transl Res. 2017 Nov 18;3(3):297-310
pubmed: 30895271
Expert Rev Vaccines. 2022 Mar;21(3):377-384
pubmed: 34913796
J Am Stat Assoc. 1996 Mar;91(433):14-28
pubmed: 12155399
Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):250-8
pubmed: 17245804
Infect Dis Rep. 2021 Mar 20;13(1):251-258
pubmed: 33804737
EClinicalMedicine. 2021 Jul;37:100941
pubmed: 34127959
Basic Clin Pharmacol Toxicol. 2021 Dec;129(6):395-396
pubmed: 34494369
Int J Biochem Cell Biol. 2005 Aug;37(8):1727-37
pubmed: 15878691
Cochrane Database Syst Rev. 2021 Mar 24;3:CD013705
pubmed: 33760236
J Clin Epidemiol. 2015 Feb;68(2):134-43
pubmed: 25579640
J Clin Pharmacol. 2021 Dec;61(12):1521-1533
pubmed: 34352112
Pharmacoepidemiol Drug Saf. 2021 Dec;30(12):1703-1715
pubmed: 34396634
Gastroenterology. 1975 Feb;68(2):392-410
pubmed: 1116684
Pharmacoepidemiol Drug Saf. 2021 Nov;30(11):1493-1503
pubmed: 34245078
J Public Health Med. 1999 Sep;21(3):299-304
pubmed: 10528957